CRO Accelovance is pairing up with a nonprofit clinical research outfit to bring its services to the developing world. Through a deal with FHI 360, Accelovance is expanding its footprint to include developing nations in Africa, Asia and South America, and the CRO's partner will get access to North America and Europe in turn. The two entities have already been collaborating on a Phase III Ebola vaccine study in West Africa, and their formalized partnership will seek to identify similar drug development needs around the world. Release